Research Use Only. Not for human or veterinary use. Not medical advice.

RC-ARA290 · Tissue Signaling Research

RC-ARA290 vial (catalog image)

RC-ARA290

Tissue Signaling Research

Catalog code Research material Lyophilized format Single catalog presentation
Presentation

Vial sizes for laboratory supply, not a protocol.

Pricing
Sign in
Researcher pricing for approved accounts
In stock
As listed on the public catalog, Nov 17, 2026
Add to cart
0 25 50 75
47 of 100

Popularity

Moderate

Public interest index

Trending down-17% vs prior 30 days

Research: Literature Activity 5/10 · Modest (PubMed volume)

Data as of Nov 17, 2026 · Sources: Wikipedia pageviews, Reddit, X public mentions.

Measures online attention only. It is not a measure of quality, purity, efficacy, or safety.

Publications per year

Unique PubMed records grouped by publication year — a volume index, not a quality rating.

PubMed counts

Last updated Nov 17, 2026. 88 unique records for (ARA-290 OR ARA290 OR "ARA 290" OR cibinetide). 2026 is a partial year. The query uses the laboratory names ARA-290 / ARA290 and the International Nonproprietary Name cibinetide. This page does not treat the named peptide as an approved drug or as a treatment. Source on PubMed

Key specifications

Catalog facts are taken from the live PEPTIDEA™ listing. Formula and molecular weight are from PubChem. Sequence is omitted here.

Catalog title
RC-ARA290 | Tissue Signaling Research
Research focus
Tissue Signaling Research
Also described as
ARA-290 · cibinetide · EPO-derived helix-B peptide
Format
Lyophilized research peptide
Catalog status
In stock (public listing)
Presentations
10 mg vial (catalog presentation)Catalog sizes, not a protocol
Molecular formula
C51H84N16O21PubChem CID 91810664 (cibinetide)
Molecular weight
1257.3PubChem average for CID 91810664
Receptor context
Described as a non-erythropoietic EPO-derived peptide that binds the innate repair receptor (EPOR / β-common receptor, CD131) in laboratory literatureLiterature description; research context only
Sequence
Not reproduced hereSee primary literature / PubChem
Researcher access
Sign-in required to view pricing
PubMed records
88 uniqueQuery above, Nov 17, 2026

Catalog notes & use limitations

Research-catalog framing only. This section does not describe effects in people or study outcomes.

Catalog notes

Listed under Tissue Signaling Research

RC-ARA290 appears in the PEPTIDEA™ Cellular Signaling Research collection with other tissue-signaling materials, including RC-BPC and RC-TB4.

Tool compound, not an approved drug

Published papers describe ARA-290 / cibinetide as an investigational, non-erythropoietic EPO-derived peptide. This page does not present it as a treatment or as an approved medicine.

10 mg catalog presentation

The public listing is a simple product. 10 mg is inferred from SKU RC-416-10. Catalog size is not a protocol.

Use limitations

Research use only

Not for human or veterinary use. Not a drug, not a cosmetic, and not medical advice. Not presented here as a treatment or weight-management product.

No outcome or dosing information

This page does not list administration amounts, schedules, or clinical results. Catalog vial sizes are presentations of the research material, not a protocol.

Confirm details from primary sources

Formula and molecular weight are cited from PubChem when a single compound applies; otherwise see the catalog notes. Sequence is omitted. Read the original papers for laboratory context — results stay in the original publications.

Specifications

Laboratory-catalog and public-chemistry details. Items without a cited source are marked.

Catalog titleRC-ARA290 | Tissue Signaling Research
CategoryTissue Signaling Research (Cellular Signaling Research)
Associated namesARA-290; cibinetide; non-erythropoietic EPO-derived peptide
FormatLyophilized research peptide
Public catalog statusIn stock (as of Nov 17, 2026)
Catalog presentations10 mg vial (catalog presentation) — sizes of the research material, not a use protocol
Molecular formulaC51H84N16O21 (PubChem CID 91810664 (cibinetide), retrieved Nov 17, 2026)
Molecular weight1257.3 (PubChem average for CID 91810664)
InChIKeyWZTIQQBMSJTRBR-WYKNNRPVSA-N (PubChem)
Receptor contextPublished papers describe ARA-290 / cibinetide as an 11-amino-acid peptide designed from the helix-B surface of erythropoietin, intended as a tool compound for the tissue-protective EPOR–CD131 heteromer without stimulating red-cell production. That is a mechanism-class description, not a use claim. It is not an approved drug.
SequenceNot reproduced on this page. See primary literature and the PubChem record.
PricingVisible after researcher sign-in
CID 91810664 (cibinetide) is cited for formula and mass. Sequence is omitted on this page.

Research literature

These are Peptidea-written summaries of selected publications, prepared so you can stay on peptidea.net. Each card describes what was studied — the research question, study type, and mechanism or setting. We do not restate results, endpoints, or protocols. Full papers remain with their publishers; a small PubMed source link is included only for citation.

Review — investigational description

van Velzen et al.

Expert Opinion on Investigational Drugs · 2014
ARA 290 described in the context of investigational small-fiber neuropathy research

This article describes ARA 290 as an investigational EPO-derived peptide and discusses its study in small-fiber neuropathy research settings. It is included as identity and literature-context material, not as a treatment recommendation for this catalog item.

Clinical-investigation findings, dosing, and any efficacy or safety conclusions in the article are not restated on this page.

Experimental, animal model

van Rijt et al.

Journal of Translational Medicine · 2013
ARA290, described as a non-erythropoietic EPO derivative, in a renal ischemia/reperfusion mouse model

This paper studied ARA290, described as a non-erythropoietic erythropoietin derivative, in a mouse model of renal ischemia and reperfusion. It is a laboratory animal study, not a clinical trial of this vial.

Injury, function, and other experimental results in the paper are not reproduced here.

Experimental, animal and cell models

Nairz et al.

Scientific Reports · 2017
Cibinetide in laboratory models of innate immune cell function

This paper examined cibinetide in experimental models of innate immune cell function. It is included as mechanism-class literature for the named peptide, not as a study of this catalog vial in people.

Immunological and disease-model findings in the paper are not restated on this page.

Experimental, animal model

Wang et al.

CNS Neuroscience & Therapeutics · 2024
The EPO-derived peptide ARA290 and the β-common receptor in a mouse cerebral-ischemia model

This paper studied ARA290 and the β-common receptor in a mouse model of cerebral ischemia. It is a laboratory animal study of receptor-pathway context, not a use guide for this material.

Histology, behavioral, and other findings in the paper are not reproduced here.

Original titles are omitted or neutralized when they use clinical-outcome wording. Counts and the optional source links use the query (ARA-290 OR ARA290 OR "ARA 290" OR cibinetide). Source on PubMed

Storage & handling

General laboratory-catalog guidance for layout purposes. Always follow the vial label and your institution’s written procedures.

  • Handle as a lyophilized research material intended for laboratory use only.
  • Store according to the conditions printed on the label and in any compound document provided to approved researchers.
  • Protect closed vials from moisture and unnecessary temperature swings.
  • If reconstitution is performed, use only the laboratory’s own written procedures. This page does not provide volumes, solvents, or working concentrations.
  • This material is not for human or veterinary use and is not medical advice.
No dosing, administration, or protocol instructions are included on this page.

Research Use Only. Not for human or veterinary use. Not medical advice. PEPTIDEA™ is a trademark of Grey Bug LLC.